Cambridge Investment Research Advisors
SIOX

Cambridge Investment Research Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,350
Closed -$11K – 2364
2018
Q4 		$11K Hold
1,350
– – ﹤0.01% 2137
2018
Q3 		$26K Buy
+1,350
New +$24.6K ﹤0.01% 2218

Other funds holding SIOX

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Cambridge Investment Research Advisors's SIOX Position: Q1 2019 in Review

Cambridge Investment Research Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2019, closing a stake of 1,350 shares — an estimated $11K sold.

Cambridge Investment Research Advisors first reported a position in SIOX in Q3 2018 and held it in 2 quarters. The position peaked at $26K in Q3 2018. 57 funds tracked by Wall St. Rank hold SIOX as of Q1 2019.

  • Cambridge Investment Research Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,350 Sio Gene Therapies Inc. Common Stock shares in Q1 2019, an estimated $11K.
  • Cambridge Investment Research Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $26K in Q3 2018.
  • 57 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2019.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2019, filed 8 May 2019.